Mitogen-activated protein kinase 14 (p38 alpha) (p38 MAPK)

Mitogen-activated protein kinase 14 (p38 alpha) is a member of the serine/threonine-protein kinase family that serves as a central integrator of cellular responses to environmental stress and inflammatory cytokines (UniProt P47811). It is activated by a variety of stimuli, including osmotic shock, heat, and pro-inflammatory signals like TNF-alpha, subsequently regulating the production of further cytokines and mediating cell cycle arrest or apoptosis (PubMed: 29330145). In pathological states, overactivation of the p38 MAPK pathway is a hallmark of chronic inflammatory diseases such as rheumatoid arthritis and chronic obstructive pulmonary disease (COPD), as well as certain cancers and neurodegenerative disorders like Alzheimer's disease (PubMed: 31963611). Therapeutic strategies have focused on small-molecule inhibitors, such as Losmapimod and Neflamapimod, which aim to reduce systemic inflammation by blocking the kinase's catalytic activity (PubChem CID 11314340). While these inhibitors have shown potent anti-inflammatory effects in preclinical models, clinical success has been limited by safety concerns like hepatotoxicity and the emergence of compensatory signaling mechanisms (PubMed: 24507153). Consequently, current research explores more selective targeting or isoform-specific inhibition to improve the therapeutic window.

Other names

MAPK14SAPK2ACSBPRKPRKM14Cytokine suppressive anti-inflammatory drug-binding proteinStress-activated protein kinase 2a

ATP-competitive inhibition or allosteric inhibition of the kinase domain to prevent phosphorylation of downstream substrates and subsequent production of pro-inflammatory cytokines.